Reid Huber, PhD, is a partner at Third Rock Ventures, one of the industry’s preeminent life sciences company creation firms based in Boston, MA, and San Francisco, CA. At Third Rock, Dr. Huber is focused on building innovative biomedical therapeutics companies across areas of high unmet medical need. In that role, Dr. Huber serves on the board of directors of MOMA Therapeutics, Tango Therapeutics, Asher Bio, Terremoto Biosciences, and Rapport Therapeutics. Prior to Third Rock, Dr. Huber was at Incyte Corporation, which he joined in 2002 as a member of the founding scientific team and, most recently, served as the company’s executive vice president and chief scientific officer. During Dr. Huber’s 17-year tenure, Incyte’s research labs discovered and advanced >25 therapeutics into clinical development, including the janus kinase inhibitors ruxolitinib (Jakafi®; approved for the treatment of myelofibrosis, polycythemia vera and graft‐versus‐host disease), baricitinib (Olumiant®; approved for the treatment of rheumatoid arthritis and alopecia areata), the FGFR inhibitor pemigatinib (Pemazyre®; approved for the treatment of cholangiocarcinoma), and the c‐MET inhibitor capmatinib (Tabrecta®; approved for the treatment of non‐small cell lung cancer).
Before joining Incyte, Dr. Huber held scientific research positions at DuPont Pharmaceuticals and Bristol‐Myers Squibb from 1997 to 2002. Dr. Huber received his PhD in molecular genetics from the Washington University School of Medicine and held pre‐ and post‐doctoral fellowships at the National Institutes of Health.